Where Does Your PCCP Live? 510(k), De Novo, and PMA Placement

Where Does a PCCP Actually Live in Your Submission?

A Predetermined Change Control Plan (PCCP) is not a standalone filing -- it is a component embedded inside a 510(k), De Novo request, or PMA. But which one, and when in that submission's own process should it be raised with FDA? Those are the practical questions this post answers. For what a PCCP is, its three required components, and whether your device needs one at all, see ADB's AI/ML SaMD regulatory strategy guide.

Submission Strategy: Where Does the PCCP Live?

A PCCP can be included in an initial 510(k), De Novo, or PMA submission, or submitted as a supplement or amendment to an existing cleared or approved device. FDA recommends using a Q-Submission (pre-submission meeting) to align on scope before you invest significant resources in drafting -- particularly for novel AI architectures or adaptive learning systems that update at the point of care.

How Placement Changes the Bar You Have to Clear

If your device cleared as a 510(k) with a substantial equivalence predicate, your PCCP's Impact Assessment must show that the changes remain within the technological characteristics and intended use envelope of that clearance. For PMA devices, the bar is higher: you must affirmatively show that the modifications do not diminish reasonable assurance of safety and effectiveness. De Novo requestors get a third posture entirely -- there is no predicate to stay within, so FDA is evaluating whether your proposed special controls (with the PCCP as one of them) are sufficient on their own.

Under 21 CFR Part 820 and the quality system framework, any software change must still be evaluated under your design change procedures regardless of which pathway carries your PCCP. A PCCP does not eliminate your QMS obligations -- it pre-authorizes specific, bounded changes at the regulatory submission level, provided your internal change controls are executed as described.

The Bottom Line

A well-executed PCCP is a competitive asset, not just a compliance exercise. It shortens your post-market iteration cycle, reduces regulatory unpredictability, and signals to FDA -- and to investors -- that your organization understands how to govern AI responsibly. But it requires precise drafting, deep integration with your quality system, and a realistic risk analysis that reflects your actual development pipeline.

At ADB Consulting & CRO Inc., Andre Butler and the team work directly with AI/ML device manufacturers to develop PCCPs that are technically rigorous and strategically aligned with your go-to-market timeline. Whether you are preparing an initial submission or retrofitting a PCCP onto an existing cleared device, we can help you get it right the first time.

Ready to build a PCCP that stands up to FDA review? Book a free discovery call with our team at adbccro.com and let's map out your regulatory strategy today.